Barclays raised the firm’s price target on Elevance Health (ELV) to $395 from $373 and keeps an Overweight rating on the shares as part of a Q3 earnings preview for the health care facilities and managed care group. The firm continues to think Medicare is the most stable, Medicaid the most uncertain, and the Affordable Care Act exchanges are inflecting positively from both a fundamental and policy perspective.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $398 from $360 at Guggenheim
- Elevance Health price target raised to $412 from $330 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer
- Health Insurance subsidies central to government shutdown negotiation, WSJ says